anonymous
Guest
anonymous
Guest
If that's true, then we are in trouble. Typical to how we do things here, upper level management in those divisions are hand-picked sycophantsThese expansions and IT investments in I&I, Rare Disease and Vaccines line up with leadership’s focus on the 12 growth brands mentioned on a couple of calls. 10 of the 12 brands are in these BUs with the addition of Eliquis and Nurtec ODT.
My guess is in the next 2-3 years, we will be a completely different company. We will probably be focused on specialty care with Oncology, Rare Disease, I&I and Vaccines. All of them focus on smaller populations with high $$$ treatments.